AYU (An International Quarterly Journal of Research in Ayurveda) · 2010 · 17 citations · 9 references
MedicineNephrologyPharmacologyDialysisHemodialysisRenal PharmacotherapyChronic Kidney DiseaseDialysis PharmacotherapyRenal DiseaseRenal PharmacologyChronic Kidney Disease ManagementChronic Kidney Disease Medication ManagementChronic Renal InsufficiencyComparative Clinical EffectivenessComparative Clinical TrialsRenal Failure ManagementTreatment Strategies
India like any other country is facing a silent epidemic of chronic renal failure (CRF)- a facet of the health transition associated with industrialization partly fuelled by increase in sedentary lifestyle, low birth weight and malnutrition. Increasing figures by many folds seen is posing a difficult situation to overcome with respect to economy and health of the working and earning population of the nation. There is an urgent need to explore, highlight new interventions and modify modifiable risk factors as a basis for treatment strategies to prevent the development and progression of CRF. The present study was taken up to evaluate the role of trial formulation tab. Punarnavadi compound in the management of chronic renal failure. This was an open clinical comparative study in controlled circumstances wherein 67 patients were studied for two months in three groups- Group A (allopathic control), Group B (ayurvedic control) and Group C (ayurvedic test). It was a multi-centric study; patients were registered from Anandababa charitable dialysis centre, Jamnagar, Kayachikitsa O.P.D. of I.P.G.T. and R.A. Jamnagar and P. D. Patel Ayurveda hospital, Nadiad. Results were assessed on 15 parameters using Students (paired) 't' test. Group A patients showed comparatively better results in eight parameters- weight, platelet count, serum urea, serum uric acid, serum sodium, potassium, chloride and total proteins. Parameter Hemoglobin% showed better results in Group B patients and in Group C patients comparatively better results in six parameters viz.- quality of life (breathlessness, weakness, general functional capacity), total count, serum creatinine and serum calcium - were observed. Throughout the study, trial drug tab. Punarnavadi compound did not show any adverse drug reaction. The results of this study will help in developing a cheap and safe treatment for the management of CRF.
9
Ömer Toprak, Hüseyin Kurt, Yasin Sarı et al. · Kidney & Blood Pressure Research · 2017 · 29.7K citations · Full text
Medicine, Endocrinology, Nutrition +17
Global burden of hypertension: analysis of worldwide data
Patricia M. Kearney, Megan Whelton, Kristi Reynolds et al. · The Lancet · 2005 · 7.7K citations
End-stage renal disease in developing countries
Vijay Kher · Kidney International · 2002 · 216 citations · Full text